HealthQuill Combination therapy
Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy failed to show “sufficient evidence” of benefit to the patients.
Drugs Health Pharma

J & J stops rheumatoid arthritis trial due to lack of ‘sufficient evidence’

Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy.

Read More
AstraZeneca Plc’s therapy for a certain type of advanced lung cancer, in combination with chemotherapy, helped patients live longer, company data from an end-stage study reveals.
Drugs Health Pharma

AstraZeneca’s therapy for a type of lung cancer helps patients live longer 

HQ Team July 21, 2025: AstraZeneca Plc’s therapy for a certain type of advanced lung cancer, in combination with chemotherapy, helped patients live.

Read More
The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.
Drugs Health Pharma

FDA gives nod for AstraZeneca’s Imfinzi to treat endometrial cancer

The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.

Read More
Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the USFDA has given the green light to the company’s Anktiva treatment.
Drugs Health Pharma

USFDA grants approval for ImmunityBio’s bladder cancer drug

HQ Team April 23, 2024: Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the.

Read More
Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received Breakthrough Therapy Designation from the USFDA.
Drugs Pharma

Moderna-Merck’s cancer vaccine gets FDA breakthrough therapy designation 

Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received.

Read More